| Literature DB >> 29580277 |
Aniek A O M Claassen1, Cornelia H M van den Ende2,3, Jorit J L Meesters4, Sanne Pellegrom4, Brigitte M Kaarls-Ohms5, Jacoba Vooijs6, Gerardine E M P Willemsen-de Mey7, Thea P M Vliet Vlieland8.
Abstract
BACKGROUND: The aim of this randomized controlled trial was to evaluate the effect of a 'supply on demand'-distribution strategy, compared to an 'unsolicited supply'-distribution strategy, on the use of a care booklet and clinical outcomes among patients with rheumatoid arthritis (RA). In addition, differences in socio-demographic and clinical characteristics between users and non-users were explored.Entities:
Keywords: Dissemination; Distribution strategy; Patient education; Rheumatoid arthritis; Self-management
Mesh:
Year: 2018 PMID: 29580277 PMCID: PMC5870684 DOI: 10.1186/s12913-018-3039-4
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Participants selection from the Sint Maartenskliniek Hospital and Leiden University Medical Centre and response rate
Demographics and characteristics of patients allocated to the two distribution strategies and as total group
| Group | Group | Total | |
|---|---|---|---|
| “unsolicited supply” | “supply on demand” | ||
| Patient characteristics | |||
| Gender (female), n (%) | 137 (70.6) | 114 (64.8) | 251 (67.8) |
| Age (years), mean (SD) | 65.0 (11.5) | 65.3 (12.4) | 65.4 (11.8) |
| Ethnicity (native), n (%) | 175 (91.2) | 157 (90.2) | 332 (90.7) |
| Married, n (%) | 132 (72.5) | 122 (72.2) | 254 (72.4) |
| Level of Education (> 12 years), n (%) | 75 (40.1) | 67 (39.0) | 142 (39.6) |
| Work (paid), n (%) | 46 (24.3) | 37 (22.4) | 83 (23.5) |
| Outpatient clinic (LUMC), n (%) | 66 (34.0) | 49 (27.8) | 115 (31.1) |
| Clinical characteristics | |||
| Disease duration (years), mean (SD) | 17.5 (11.9) | 16.4 (12.9) | 17.0 (12.4) |
| Disease activity, RADAI (0–10), mean (SD) | 2.5 (1.9) | 2.8 (2.0) | 2.6 (1.9) |
| Activity limitations HAQ-DI (0–3), mean (SD) | 0.9 (0.7) | 0.9 (0.7) | 0.9 (0.7) |
| Medication, n (%) | |||
| NSAIDs | 66 (34.0) | 62 (35.2) | 128 (34.6) |
| Corticosteroid | 33 (17.0) | 27 (15.3) | 60 (16.22) |
| DMARDs | 131 (67.5) | 123 (69.9) | 254 (68.65) |
| Biologicals | 82 (42.3) | 87 (49.4) | 169 (45.68) |
| Care booklet | |||
| Ordered the care booklet, n (%) | – | 106 (60.2) | – |
| Care booklet, n (%) | |||
| Non-user | 139 (76.8) | 134 (78.4) | 273 (77.6) |
| User | 42 (23.2) | 37 (21.6) | 79 (22.4) |
RADAI Rheumatoid Arthritis Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index
Differences in secondary outcomes between the two distribution strategies
| Group | Group | Difference (95% CI) | |
|---|---|---|---|
| Educational needs, D-ENAT(0–156), mean (SD) | 81.3 (26.9) | 75.7 (27.5) | −4.2 (−9.9–1.5) |
| Self-efficacy, GSES, mean (SD) | 32.4 (5.7) | 32.6 (5.4) | 0.2 (−1.0–1.3) |
| Illness perceptions, IPQ-R, mean (SD) | |||
| Timeline (6–30) | 24.7 (4.6) | 24.4 (5.4) | −0.4 (−1.3–0.6) |
| Consequences (4–20) | 18.9 (4.8) | 18.8 (4.5) | − 0.1 (− 1.1–0.9) |
| Timeline cyclical (6–30) | 13.9 (3.4) | 14.2 (3.5) | 0.3 (− 0.4–1.0) |
| Personal control (6–30) | 19.0 (3.6) | 19.7 (3.6) | 0.7 (0.0–1.5) |
| Treatment control (5–25) | 17.8 (2.9) | 17.9 (3.0) | 0.1 (− 0.5–0.7) |
| Illness coherence (5–25) | 17.6 (3.8) | 17.4 (3.6) | − 0.2 (− 1.0–0.6) |
| Emotional representation (6–30) | 13.8 (4.3) | 14.1 (4.1) | 0.3 (− 0.6–1.1) |
D-ENAT (Dutch) Educational Needs Assessment Tool, GSES General Self-efficacy Scale, IPQ-R Revised Illness Perception Questionnaire
Differences in patient and clinical characteristics between users and non-users of the care booklet
| Non-users | Users | OR (95% CI) | |
|---|---|---|---|
| Patient characteristics | |||
| Gender ( | 182 (66.7) | 58 (73.4) | 1.4 (0.8–2.4) |
| Age | 65.3 (12.2) | 64.7 (9.6) | Δ − 0.7 (−3.7–2.3) |
| Ethnicity ( | 27 (10.0) | 6 (7.7) | 0.8 (0.3–1.9) |
| Married, n (%) | 181 (69.4) | 64 (84.2) | 2.4 (1.2–4.6)** |
| Level of education | 106 (39.9) | 32 (41.6) | 1.1 (0.6–1.8) |
| Clinical characteristics | |||
| Disease duration | 17.3 (12.8) | 15.9 (11.2) | Δ −1.5 (−4.6–1.7) |
| Disease activity, RADAI (0–10), mean (SD) | 2.5 (1.9) | 3.0 (2.0) | Δ 0.5 (0.0–1.1)** |
| Activity limitations HAQ-DI (0–3), mean (SD) | 0.9 (0.7) | 1.1 (0.7) | Δ 0.2 (0.1–0.4)** |
| Medication, n (%) | |||
| NSAIDs | 97 (35.5) | 29 (36.7) | 1.0 (0.6–1.7) |
| Corticosteroid | 39 (14.3) | 19 (24.1) | 1.9 (1.0–3.5)** |
| DMARDs | 185 (67.8) | 58 (73.4) | 1.3 (0.8–2.3) |
| Biologicals | 123 (45.1) | 42 (53.2) | 1.4 (0.8–2.3) |
| Educational needs, D-ENAT(0–156), mean (SD) | 75.3 (27.5) | 86.0 (26.6) | Δ 9.7 (2.9–16.6)** |
| Self-efficacy, GSES, mean (SD) | 32.3 (5.9) | 33.1 (4.1) | Δ 0.8 (−0.6–2.2) |
| Illness perceptions, IPQ-R, mean (SD) | |||
| Timeline (6–30) | 24.5 (4.6) | 25.1 (3.9) | Δ 0.6 (−0.5–1.8) |
| Consequences (4–20) | 18.6 (4.7) | 19.8 (4.5) | Δ 1.3 (−0.2–2.3) |
| Timeline cyclical (6–30) | 13.6 (3.6) | 15.1 (3.0) | Δ 1.4 (0.5–2.3)** |
| Personal control (6–30) | 19.2 (3.7) | 19.6 (3.5) | Δ 0.4 (−0.5–1.3) |
| Treatment control (5–25) | 17.8 (3.0) | 17.9 (2.7) | Δ 0.1 (−0.6–0.9) |
| Illness coherence (5–25) | 17.4 (3.7) | 18.0 (3.5) | Δ 0.5 (−0.5–1.4) |
| Emotional representation (6–30) | 13.9 (4.3) | 14.0 (3.6) | Δ 0.1 (−1.0–1.1) |
D-ENAT (Dutch) Educational Needs Assessment Tool, RADAI Rheumatoid Arthritis Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index, GSES General Self-efficacy Scale, IPQ-R Revised Illness Perception Questionnaire
**Significant for p-value ≤0.05